Clinical trials: Scalp Psoriasis
Psoriasis Vulgaris
Long-term Treatment of Scalp Psoriasis With Xamiol® Gel in a Large Adult Chinese Population
A phase 4 trial comparing the safety and efficacy of treatment with Xamiol® gel (calcipotriol 50 mcg/g plus betamethasone 0.5 mg/g (as dipropionate)) once daily (as required) with Daivonex® scalp solution (calcipotriol 50 mcg/g)…
- Trial name
- NCT02533973
- Testing
- Xamiol® gel, Daivonex® scalp solution
- Where
- China
- Volunteers
- 951 people
- Sponsor
- LEO Pharma
Psoriasis
The Purpose of This Study is to Demonstrate the Safety and Effectiveness of Calcipotriene Foam in Subjects With Scalp and Body Psoriasis
The purpose of this study is to determine the safety and effectiveness in the treatment of psoriasis on the scalp and on the body.
- Trial name
- NCT01139580
- Testing
- Calcipotriene Foam, Vehicle Foam
- Where
- 26 sites in United States
- Volunteers
- 363 people
- Sponsor
- Stiefel, a GSK Company
Seborrheic Dermatitis, Psoriasis of Scalp
Study to Evaluate the Safety of Sebryl® and Sebryl Plus® in Seborrheic Dermatitis and Psoriasis of Scalp
Observational, descriptive, retrospective, multicenter study to evaluate the safety of the treatment with Sebryl® and / or Sebryl Plus® in the management of seborrheic dermatitis and psoriasis of the scalp in routine medical…
- Trial name
- NCT05105139
- Testing
- Allantoin/ Coal Tar/ Clioquinol, Allantoin/ Coal Tar/ Clioquinol/ Triclosan
- Where
- Mexico
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Laboratorios Silanes S.A. de C.V.
Plaque Psoriasis, Psoriatic Arthritis
Real-World Study of Xeligekimab for Moderate to Severe Plaque Psoriasis(XP-Real)
Xeligekimab Injection was approved in China on August 20, 2024, for treating adults with moderate to severe plaque psoriasis who are candidates for systemic treatment or phototherapy.
- Conditions
- Plaque Psoriasis, Psoriatic Arthritis, Scalp Psoriasis, Nail Psoriasis
- Trial name
- NCT06802848
- Testing
- Xeligekimab injection
- Where
- China
- Volunteers
- 1,000 people
- Sponsor
- Chongqing Genrix Biopharmaceutical Co., Ltd
Scalp Psoriasis
Safety Study in Patients With Scalp Psoriasis Suppression Following Maximal Use Treatment With Topical Product
An Open-Label, Safety Study to Assess the Potential for Adrenal Suppression Following Maximal Use DSXS topical product (Taro Pharmaceuticals U.S.A., Inc.) in Patients with Moderate to SevereScalp Psoriasis
- Trial name
- NCT02933502
- Testing
- DSXS topical product
- Where
- United States
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Scalp Psoriasis
Subject Preference for Scalp Psoriasis Treatment
The scalp is one of the most common affected sites in psoriatic patients as 79% of them have scalp involvement.It has also a psychological aspect with 31% of patients with scalp psoriasis indicating distress.
- Trial name
- NCT00438399
- Testing
- C. propionate - Corticosteroid 1, C. propionate- Corticosteroid 2, C. propionate -Corticosteroid 3
- Where
- Italy
- Volunteers
- 219 people
- Sponsor
- Galderma R&D
Plaque Psoriasis
A Randomized Double Blind Vehicle Controlled Dose Ranging Parallel Design Multiple Site Clinical Study
The objectives of this study are to evaluate the therapeutic efficacy and safety of DSXS and a Placebo in patients with moderate to severe scalp psoriasis.
- Trial name
- NCT02413229
- Testing
- DSXS1411
- Volunteers
- 151 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Scalp Psoriasis
BE Study of Calcipotriene Hydrate and Betamethasone Dipropionate Topical Suspension in the Treatment of Scalp Psoriasis
This study will be conducted to evaluate the therapeutic bioequivalence of a TEST formulation of calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064% to the RLD.
- Trial name
- NCT03122353
- Testing
- Calcipotriene and betamethasone suspension, Taclonex
- Where
- 34 sites in United States
- Volunteers
- 699 people
- Sponsor
- Tolmar Inc.
Psoriasis
A Study of the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Moderate to Severe Plaque Psoriasis of the Scalp
This is a Phase 3, multicenter, randomized, placebo-controlled, double-blind study of the efficacy and safety of apremilast (CC-10004) in subjects with moderate to severe plaque psoriasis of the scalp.
- Trial name
- STYLE (NCT03123471)
- Testing
- Apremilast
- Where
- 45 sites in United States, Canada
- Volunteers
- 303 people
- Sponsor
- Amgen
Scalp Psoriasis
Study to Evaluate Efficacy and Safety of the Topical Product in Patients With Mild to Severe Scalp Psoriasis
A Randomized Double-Blind, Vehicle-Controlled, Parallel Design, Multiple-Site, Phase III Clinical Study
- Trial name
- NCT02932462
- Testing
- DSXS
- Volunteers
- 373 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Scalp Psoriasis
Safety and Efficacy of LEO 80185 Gel in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis
The purpose of the study is to evaluate the safety and efficacy of once daily use of LEO 80185 gel in adolescent subjects (aged 12 to 17) with scalp psoriasis.
- Trial name
- NCT01120223
- Testing
- LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)
- Where
- 17 sites in Canada, France and 1 more
- Volunteers
- 78 people
- Sponsor
- LEO Pharma
Plaque Psoriasis
Real-life Evaluation of the Daivobet® Gel Applicator
This study aims to describe the patient population being treated and evaluate their treatment adherence and treatment outcomes during treatment of scalp psoriasis with Daivobet® gel Applicator for 4 weeks.
- Trial name
- ASAP PSO (NCT02856542)
- Testing
- calcipotriol/betamethasone dipropionate gel in Applicator
- Where
- France
- Volunteers
- 1,560 people
- Sponsor
- LEO Pharma
Scalp Psoriasis
To Study Generic Calcipotriene and Betamethasone Dipropionate Topical Suspension, 0.005%/0.064%, in the Treatment of Scalp Psoriasis
This is a phase III, randomized, double-blind, placebo-controlled, parallel- group, multiple-site study to evaluate the therapeutic equivalence of generic calcipotriene and betamethasone dipropionate topical suspension…
- Trial name
- NCT03331523
- Testing
- Calcipotriene/Betamethasone Dipropionate, Taclonex®
- Where
- 31 sites in United States
- Volunteers
- 643 people
- Sponsor
- Glenmark Pharmaceuticals Ltd. India
Psoriasis, Psoriatic Arthritis
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
This study will test the clinical effectiveness and safety of apremilast compared with placebo as well as etanercept compared with placebo in the same group of patients with moderate to severe plaque psoriasis.
- Trial name
- NCT01690299
- Testing
- Apremilast, Etanercept
- Where
- 82 sites in United States, Australia and 9 more
- Volunteers
- 250 people
- Sponsor
- Amgen
Scalp Psoriasis
Clobetasol Propionate Spray Versus Vehicle Spray for the Management of Moderate to Severe Plaque Psoriasis of the Scalp
The primary objective of this study is to evaluate the safety and efficacy of clobetasol propionate spray versus vehicle spray for the management of moderate to severe plaque psoriasis of the scalp.
- Trial name
- NCT00881868
- Testing
- clobetasol propionate spray 0.05%, Vehicle spray
- Where
- 4 sites in United States
- Volunteers
- 81 people
- Sponsor
- Galderma R&D
Psoriasis
Study to Test the Effectiveness of a New Treatment for Scalp Psoriasis
The purpose of this study is to test the effectiveness of DermiPsor's DPS-102 (test product) in patients with scalp Psoroasis. The study is also intended to assess the safety of the product.
- Trial name
- NCT01368887
- Testing
- DPS-102, Calcipotriol Monotherapy, Nicotinamide Monotherapy
- Where
- 2 sites in United States
- Volunteers
- 160 people
- Sponsor
- DermiPsor, Ltd.
Psoriasis
Moderate to Severe Plaque Psoriasis With Scalp Involvement
The purpose of this study is to determine if etanercept is effective in the treatment of scalp involvement in moderate to severe plaque psoriasis.
- Trial name
- NCT00791765
- Testing
- Etanercept
- Volunteers
- 124 people
- Sponsor
- Amgen
Psoriasis Vulgaris
LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)
The purpose of this study is to compare the efficacy and safety of Calcipotriol 50 Mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension with the active components when used individually as monotherapy in the…
- Trial name
- NCT01188928
- Testing
- Calcipotriol plus betamethasone, Betamethasone-17,21-dipropionate, Calcipotriene
- Where
- 59 sites in United States
- Volunteers
- 1,152 people
- Sponsor
- LEO Pharma
Plaque Psoriasis
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
The purpose of the study is to see how effective JNJ-77242113 is in participants with plaque psoriasis affecting special areas (scalp, genital, and/or palms of the hands and the soles of the feet).
- Trial name
- ICONIC-TOTAL (NCT06095102)
- Testing
- JNJ-77242113
- Where
- 90 sites in United States, Argentina and 9 more
- Volunteers
- 311 people
- Sponsor
- Janssen Research & Development, LLC
Psoriasis of Scalp
Efficacy of Calcipotriol Plus Betamethasone Gel Versus Calcipotriol Scalp Solution in Scalp Psoriasis
The purpose of this study is to evaluate whether once daily treatment for up to 8 weeks of calcipotriol plus betamethasone dipropionate gel is more effective than twice daily treatment of calcipotriol scalp solution in patients…
- Trial name
- NCT00243464
- Testing
- Calcipotriol plus betamethasone dipropionate (LEO80185 gel)
- Where
- 5 sites in Belgium, Canada and 3 more
- Volunteers
- 300 people
- Sponsor
- LEO Pharma